Walleye Capital
ARQT icon

Walleye Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Walleye Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,800
Closed -$66K – 4723
2026
Q1 		$66K Sell
2,800
-3,500
-56% -$89.3K ﹤0.01% 3815
2025
Q4 		$183K Buy
6,300
+1,300
+26% +$33.3K ﹤0.01% 3579
2025
Q3 		$94.3K Sell
5,000
-13,500
-73% -$213K ﹤0.01% 3733
2025
Q2 		$259K Buy
+18,500
New +$259K ﹤0.01% 3172

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Walleye Capital's ARQT Position: Q2 2026 in Review

Walleye Capital increased its Arcutis Biotherapeutics (ARQT) stake by 415% in Q2 2026, buying an estimated $4.88M and bringing the position to 260,033 shares worth $6.82M. The position accounts for 0.02% of the portfolio, ranked #654.

Walleye Capital first reported a position in ARQT in Q4 2021 and has held it in 9 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Walleye Capital held 260,033 shares of Arcutis Biotherapeutics worth $6.82M as of Q2 2026.
  • Walleye Capital bought 209,573 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.88M.
  • Arcutis Biotherapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #654 holding.
  • Walleye Capital first reported a position in Arcutis Biotherapeutics in Q4 2021 and has held it in 9 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.